DataMeds AI, Inc. has entered into a significant non-binding agreement aimed at acquiring key intellectual property assets and expanding its partnerships. This strategic move, outlined in a recent SEC filing, is expected to reshape the company's operations and enhance its offerings in the pharmacy sector.
The agreement, known as the non-binding Second Amended and Restated Letter of Intent (LOI), was executed on October 21, 2026. It involves acquiring certain Quality of Life Peace of Mind (QLPM) intellectual property assets from EOS Technology Holdings, Inc. and Scilex Holding Company. Additionally, the company plans to expand its existing PharmacyChain license with Datavault AI Inc. and acquire a controlling interest in Health Lives Here through an exchange of membership interests.
Background
DataMeds AI, Inc. operates in the wholesale drugs sector, specifically categorized under the SIC code 5122, which includes drugs, proprietaries, and druggists' sundries. The company, traded on the Nasdaq under the ticker symbol MEDS, has undergone several name changes in recent years, transitioning from Wellgistics Health, Inc. to its current name.
In its recent filings, DataMeds has shown a commitment to expanding its business through strategic partnerships and acquisitions. The company has previously filed multiple 8-K forms detailing its ongoing negotiations and agreements.
What the Filing Says
The SEC filing states, "As previously disclosed, DataMeds AI, Inc. entered into a Fully Binding Term Sheet... with EOS, Scilex, Datavault, and HBA." The filing continues to outline the terms of the non-binding Second Amended and Restated LOI, emphasizing the potential for significant changes in ownership and business structure.
According to the filing, the company anticipates issuing shares of its common stock as part of the transaction, which would result in the new stakeholders owning approximately 89.5% of the company post-closing. This includes various ownership percentages for EOS, Scilex, Datavault, and others involved in the transaction.
Impact
This agreement may significantly affect DataMeds' current shareholders and stakeholders in the wholesale drugs industry. The anticipated changes in ownership could lead to a shift in corporate governance and strategic direction, impacting how the company operates in a competitive market.
Additionally, the royalties outlined in the agreement, including a 6% royalty to REBOOT Health AI and a 5% royalty to both EOS and Scilex, suggest that DataMeds will have ongoing financial obligations tied to the newly acquired intellectual property.
What's Next
The filing indicates that the completion of the transaction is contingent upon obtaining necessary stockholder approvals and meeting Nasdaq's requirements. If these approvals are not secured, the parties involved may terminate the non-binding Second A&R LOI without liability.
As the company moves forward, further filings and definitive agreements are expected to clarify the terms and conditions of the transaction, shaping the future of DataMeds AI, Inc. and its role in the wholesale drugs sector.